Twist Bioscience (NASDAQ:TWST) Cut to In-Line at Evercore

Twist Bioscience (NASDAQ:TWST) was downgraded by investment analysts at Evercore from an “outperform” rating to an “in-line” rating in a research report issued on Monday. They presently have a $102.00 price target on the stock. Evercore’s target price would suggest a potential upside of 2.78% from the company’s current price.

Several other equities analysts also recently commented on the company. Canaccord Genuity Group assumed coverage on Twist Bioscience in a research report on Monday, June 15th. They issued a “buy” rating and a $90.00 price objective on the stock. Barclays lifted their target price on Twist Bioscience from $65.00 to $95.00 and gave the company an “overweight” rating in a research note on Wednesday, June 24th. TD Cowen upped their price target on Twist Bioscience from $68.00 to $89.00 and gave the stock a “buy” rating in a research note on Monday, June 15th. Piper Sandler assumed coverage on shares of Twist Bioscience in a research report on Thursday, June 11th. They set an “overweight” rating and a $85.00 price objective on the stock. Finally, Leerink Partners set a $80.00 target price on shares of Twist Bioscience in a report on Friday, May 22nd. Eight investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $84.30.

Twist Bioscience Price Performance

TWST stock opened at $99.24 on Monday. The business’s 50-day moving average price is $70.97 and its 200-day moving average price is $53.99. The stock has a market cap of $6.18 billion, a P/E ratio of -74.62 and a beta of 2.11. The company has a quick ratio of 2.42, a current ratio of 2.70 and a debt-to-equity ratio of 0.03. Twist Bioscience has a twelve month low of $23.30 and a twelve month high of $105.47.

Twist Bioscience (NASDAQ:TWST) last posted its quarterly earnings results on Monday, May 4th. The company reported ($0.71) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.49) by ($0.22). The firm had revenue of $110.72 million during the quarter, compared to the consensus estimate of $107.64 million. Twist Bioscience had a negative return on equity of 26.73% and a negative net margin of 19.85%.The business’s revenue for the quarter was up 19.3% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($0.66) earnings per share. On average, equities research analysts forecast that Twist Bioscience will post -2.02 EPS for the current year.

Insider Buying and Selling

In other Twist Bioscience news, CEO Emily M. Leproust sold 18,880 shares of Twist Bioscience stock in a transaction on Thursday, June 25th. The shares were sold at an average price of $95.00, for a total value of $1,793,600.00. Following the completion of the transaction, the chief executive officer directly owned 824,039 shares of the company’s stock, valued at $78,283,705. This trade represents a 2.24% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Paula Green sold 291 shares of the stock in a transaction dated Monday, June 22nd. The shares were sold at an average price of $87.32, for a total transaction of $25,410.12. Following the completion of the transaction, the senior vice president directly owned 120,414 shares of the company’s stock, valued at approximately $10,514,550.48. The trade was a 0.24% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 67,580 shares of company stock valued at $5,169,482 in the last three months. Corporate insiders own 3.08% of the company’s stock.

Institutional Investors Weigh In On Twist Bioscience

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. EdgePoint Investment Group Inc. increased its position in shares of Twist Bioscience by 71.1% during the 3rd quarter. EdgePoint Investment Group Inc. now owns 4,082,319 shares of the company’s stock valued at $114,876,000 after purchasing an additional 1,696,377 shares during the last quarter. First Light Asset Management LLC boosted its stake in Twist Bioscience by 26.4% during the third quarter. First Light Asset Management LLC now owns 1,194,883 shares of the company’s stock worth $33,624,000 after buying an additional 249,850 shares during the period. SG Americas Securities LLC boosted its stake in Twist Bioscience by 350.3% during the fourth quarter. SG Americas Securities LLC now owns 76,484 shares of the company’s stock worth $2,426,000 after buying an additional 59,500 shares during the period. UBS Group AG raised its stake in shares of Twist Bioscience by 28.6% in the fourth quarter. UBS Group AG now owns 662,317 shares of the company’s stock valued at $21,009,000 after acquiring an additional 147,389 shares during the period. Finally, Pictet Asset Management Holding SA lifted its holdings in shares of Twist Bioscience by 108.5% in the 4th quarter. Pictet Asset Management Holding SA now owns 222,647 shares of the company’s stock worth $7,302,000 after acquiring an additional 115,880 shares during the last quarter.

Twist Bioscience Company Profile

Twist Bioscience Corporation is a synthetic biology company specializing in the development and commercialization of DNA-based products and solutions. Founded in 2013 and headquartered in South San Francisco, California, the company has pioneered a proprietary silicon-based DNA synthesis platform designed for high-throughput production of synthetic genes and oligonucleotides. Twist leverages semiconductor manufacturing techniques to enable precise, scalable synthesis of DNA at speeds and volumes unattainable with traditional methods.

At the core of Twist’s offering is its proprietary platform that automates the synthesis of custom DNA fragments, gene libraries, and long oligonucleotides.